ClinicalTrials.gg
RecruitingNCT05264779Updated Oct 30, 2026

The Periviable GOALS Decision Support Tool

An interventional study of Periviable GOALS DST in Pregnancy Preterm, Premature Birth and Pregnancy Complications, sponsored by Indiana University. Recruiting at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Indiana University · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.
Updated Oct 30, 2026Site recruiting status changedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 742 studies in Premature Birth with a site in United States — 103 open to participants now, 136 under way, 9 of them phase 3. Premature Birth · United States.

Planned enrollment
104th of 529
300 · median 85
Started
2022
with 29 others
No phase
357 of 742
52 open now
Primary completion
2027-11
later than 87 of 135 live
Registered
613th of 742
by date

Among the 742 studies in Premature Birth with a site in United States, this one is the 104th largest by planned enrollment of the 529 interventional ones that give a count, is one of 30 that started in 2022, is one of 357 with no phase, reaches primary completion later than 87 of the 135 other live ones, and was the 613th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

103 of the 742 studies in Premature Birth with a site in United States are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 742 studies in Premature Birth with a site in United States, or all of them as a file.
02

Study summary

The Periviable GOALS (Getting Optimal Alignment around Life Support) decision support tool (DST) is meant to facilitate informed shared decision-making regarding neonatal resuscitation for families facing the threat of a periviable delivery (deliveries occurring between 22 0/7 - 25 6/7 weeks gestational age). It is designed for parents to review independent of their clinician, and is intended to supplement, not replace, clinician counseling. The focus of the DST is the provision of patient-centered outcomes information and assistance with values clarification regarding neonatal outcomes. This is a multisite, randomized controlled trial to test the effect of the Periviable GOALS DST on shared decision making and decision satisfaction. The investigators hypothesize that participants who utilize the GOALS DST will have improved shared decision making and higher decision satisfaction.

Read the detailed description

The investigators will evaluate the Periviable GOALS DST in a randomized controlled trial among 144 pregnant patients between 22 0/7 and 25 6/7 weeks gestation who are hospitalized for a pregnancy complication that threatens periviable delivery. Pregnant patients agreeing to participate will be asked to identify whom they will primarily rely on for assistance in making decisions regarding their delivery plan (e.g., father of the baby, partner, a family member, or any other important individual in the patient's life), referred to as the 'important other' (IO). In terms of IO recruitment goals, the investigators anticipate recruiting 72 IOs. This goal is based on our previous work with a similar population of pregnant patients, in which about half identified an 'important other' to be included in the study.

Recruitment will be conducted at Indiana University (IU), the University of California at San Francisco (UCSF), the University of Kansas, the University of California at San Diego (UCSD), Northwestern University, The Ohio State University (OSU), the University of Pennsylvania (UPenn), The University of Texas at Austin (UTA), Yale University, University of Massachusetts (UMass), the University of Kentucky (UK), and Brown University.

This study consists of 3-4 points of data collection, depending on group assignment. Participants will be randomized into a treatment group or control group at the start of the study. All participants will complete the T0 interview, which consists of a set of baseline questionnaires and survey instruments that will be administered in-person, prior to delivery and after they have been counseled on their neonatal treatment options. Immediately following T0, participants who are assigned to the control group will proceed with usual care. Participants who are randomized to the intervention will review the Periviable GOALS DST, which contains outcomes information, values clarification and embedded short documentary style videos. The content focuses largely on helping patients better understand the choice they have between comfort care and life-sustaining efforts in the context of periviable delivery. After viewing the DST, participants will repeat instruments from T0 and provide feedback regarding the tool's acceptability (T1). Another member of the research team will contact all participants to complete follow-up interviews to assess decision quality, neonatal treatment preference and outcome, and mental health. These interviews will be conducted on postpartum day 1 or 2 (T2), at three months postpartum (T3), and at six months postpartum (T4).

03

Conditions studied

  • Pregnancy Preterm
  • Premature Birth
  • Pregnancy Complications
  • Obstetric Labor, Premature
  • Obstetric Labor Complications

Keywords

  • Decision making
  • Periviable delivery
  • Preterm birth
  • Risk Communication
  • Neonatal Resuscitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for Pregnant Persons:

  • Adults (18 years or older)
  • Pregnant between 22 0/7 to 25 6/7 weeks gestation (this window may be slightly different for each recruitment site, as the gestational window that defines periviable delivery varies by institution).
  • Presenting to Labor \& Delivery at an approved study site with a pregnancy complication that poses the potential threat of or need for periviable delivery (e.g., rupture of membranes, preterm labor, shortened cervix, pre-eclampsia, and growth restriction).
  • Must have been counseled on their neonatal treatment options (e.g. resuscitation, comfort care) by their healthcare team prior to being approached by the study team.

Inclusion Criteria for Important Others:

  • Adults (18 years or older)
  • 1 per pregnant person
  • Is identified by the pregnant person as someone who will be involved in making decisions for the baby
  • Must be present at the time of randomization to participate

Exclusion Criteria:

  • Under 18 years of age
  • Incarcerated
  • Medically unstable (i.e. in active labor and dilated 6cm or more)
  • Emotionally unstable
  • Have not been counseled by their healthcare team regarding neonatal treatment options
  • Are not admitted to Labor \& Delivery for reasons indicative of a threatened early delivery
  • If they are experiencing a known fatal fetal anomaly
  • Are not present at the time of randomization (only for important others)
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • No intervention
    Usual Care (control)

    Participants assigned to this group will proceed with usual medical care and treatment, consisting of counseling by the teams of obstetricians and/or neonatologists at the respective study sites.

  • Experimental
    Periviable GOALS DST Group

    Participants randomized to the intervention will be presented with the Periviable GOALS DST and instructed to review the DST in its entirety. The participant will complete the education and values clarification components of the DST with the Recruitment RA present to confirm completion. Following completion of the GOALS DST, the Recruitment RA will repeat knowledge and decisional conflict instruments and assess acceptability.

    Other: Periviable GOALS DST

Interventions

  • OtherPeriviable GOALS DST

    An iPad application that contains outcomes information, values clarification and embedded short documentary style videos. The tool was designed with low-literacy and low-numeracy populations in mind, and utilizes graphics and video content to enhance meaning-making of complex medical information and jargon. The GOALS DST refers patients back to their physicians to discuss specific treatment options, local outcomes, and management strategies available to them. The DST's content focuses largely on helping patients better understand the choice they have between comfort care and life-sustaining efforts in the context of periviable delivery.

06

What researchers measure

Primary outcomes

  1. Shared Decision Making

    9-item Shared Decision Making Questionnaire (SDM-Q-9) administered in-person or via phone/Zoom call. Scores range from 0 to 100, with a higher score correlating to higher shared decision making.

    Time frame: 1 day to 2 weeks after delivery

  2. Decision Satisfaction

    6-item Satisfaction with Decision Scale, administered in-person or via phone/Zoom call at three time points. There are 5 response categories ranging from 1 (strongly disagree) to 5 (strongly agree) with higher scores correlating to higher decision satisfaction.

    Time frame: 1 day to 2 weeks after delivery

Secondary outcomes

  1. Decisional Conflict

    16-item Decisional Conflict Scale (DCS) administered during Zoom interview. There are 5 response categories, ranging from 0 (no decisional conflict) to 100 (extremely high decisional conflict).

    Time frame: 1 day to 2 weeks after delivery, 3 months after delivery, and 6 months after delivery

  2. Knowledge about Periviable Delivery

    21-item knowledge scale, administered in-person prior to delivery. Scores range from 0-21 with higher scores indicating greater knowledge.

    Time frame: Before delivery

  3. Decision Regret

    5-item Decision Regret Scale, administered in person or via phone/Zoom call at three time points. There are 5 response categories ranging from 1 (strongly agree) to 5 (strongly disagree) with higher scores correlating to higher decision regret.

    Time frame: 1 day to 2 weeks after delivery, 3 months after delivery, and 6 months after delivery

  4. Decision Control

    5-item subscale from the Decision Evaluation Scale, administered in-person or via phone/Zoom call at three time points. There are five responses ranging from 1 (strongly disagree) to 5 (strongly agree) with higher scores correlating to lower decision control.

    Time frame: 1 day to 2 weeks after delivery, 3 months after delivery, and 6 months after delivery

  5. Depression

    9-item Patient Health Questionnaire (PHQ-9), administered in-person and via phone/Zoom calls at four time points. Participants are asked to indicate how much they have been bothered by a list of problems over the last two weeks. There are 4 response ranging from 0 (not at all) to 4 (nearly every day). Total scores range from 0-27 and are organized into 5 categories: minimal depression (0-4), mild depression (5-9), moderate depression (10-14), moderately severe depression (15-19), and severe depression (20-27).

    Time frame: Before delivery, up to 2 weeks postpartum, 3 months postpartum, and 6 months postpartum.

  6. Anxiety

    7-item Generalized Anxiety Disorder (GAD-7), administered in-person and via phone/Zoom calls at four time points. Participants are asked to indicate how much they have been bothered by a list of problems over the last two weeks. There are 4 responses ranging from 0 (not at all) to 4 (nearly every day). Total scores range from 0-21 and are organized into 4 categories: minimal anxiety (0-4), mild anxiety (5-9), moderate anxiety (10-14), and severe anxiety (15-21).

    Time frame: Before delivery, up to 2 weeks postpartum, 3 months postpartum, and 6 months postpartum.

  7. Post-Traumatic Stress Disorder

    22-item Impact of Events Scale-Revised (IES-R), administered in-person or via phone/Zoom call. Participants are asked to indicate how much they were distressed or bothered during the past seven days by each difficulty listed, in relation to losing their child to periviable delivery or their delivery experience (if their child survived). There are 5 response categories ranging from 0 (not at all) to 4 (extremely) with total scores ranging from 0-88. Scores of 33 or higher indicates a probable diagnoses for PTSD.

    Time frame: Before delivery, up to 2 weeks postpartum, 3 months postpartum, and 6 months postpartum.

  8. Number of Parents who Preferred Resuscitation vs. Palliation

    Medical records will be reviewed for documentation of parental treatment preference (attempt resuscitation vs. palliation), treatment provided, and neonatal outcome (death, neurodevelopmental impairment, gestational age at delivery). The investigators will also assess treatment preferences at the first interview to account for baseline difference. To do so, participants will be asked whether they have been asked to make any treatment decisions regarding their baby, and if so, the types of decisions they were asked to make. If the participant identifies resuscitation versus palliative care as a decision they have been asked to make, they will be asked about their preference regarding these two options. If they make no mention of resuscitation the investigators will ask if the doctors have discussed resuscitation (Y/N), comfort care (Y/N), and then ask if they have decided which treatment option they prefer (Resuscitation, Comfort Care, Undecided).

    Time frame: Before delivery and 1-2 days after delivery

  9. Neonatal Treatment Provided

    Medical records will be reviewed for documentation of neonatal treatment provided (resuscitation vs. palliation).

    Time frame: Up to 6 months after delivery

  10. Neonatal Outcome

    Medical records will be reviewed for documentation of neonatal outcome (death, neurodevelopmental impairment, gestational age at delivery).

    Time frame: Up to 6 months after delivery

  11. Acceptability of the decision support tool

    Decision Aid Acceptability Questionnaire that elicits feedback from viewers of the GOALS DST including acceptability of format, whether the information was presented in a balanced/fair manner, clarity of information, helpfulness of the DST, and whether users would recommend it to other parents. Will be administered in-person, immediately following viewing the Periviable GOALS DST.

    Time frame: Before delivery

  12. Preparation for Decision Making

    10-item Preparation for Decision Making Scale (PrepDM) that covers all of the core attributes for assessing the quality of the decision-making process except the extent to which patients feel informed about options and outcomes. Will be administered in-person, immediately following viewing the Periviable GOALS DST. There are 5 response categories ranging from 1 (not at all) to 5 (a great deal) with higher scores indicating higher perceived level of preparation for decision making.

    Time frame: Before delivery

  13. Decision Satisfaction

    6-item Satisfaction with Decision Scale, administered in-person or via phone/Zoom call at three time points. There are 5 response categories ranging from 1 (strongly disagree) to 5 (strongly agree) with higher scores correlating to higher decision satisfaction.

    Time frame: 3 months and 6 months after delivery

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Participant data will only be shared with approved members of the study team.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Nov 2027, 65 months after the start.

Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 65 months is above that.

Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Aug 2026 → Nov 2027 and completion Feb 2027 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2021
First posted
Mar 3, 2022
StartActual
Jun 6, 2022
Primary completionEst.
Nov 2027was Aug 2026
CompletionEst.
Aug 2028was Feb 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Brown University is now Recruiting
Oct 30, 2026
Primary completion
Aug 2026→Nov 2027
Oct 30, 2026
Study completion
Feb 2027→Aug 2028
Oct 30, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Brown University · Providence, United StatesContact m•••@carene.org→A•••@carene.org
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Brown University is now Recruiting
    Primary completion Aug 2026→Nov 2027
    Study completion Feb 2027→Aug 2028
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Brown University · Providence, United StatesContact m•••@carene.org→A•••@carene.org
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05264779
Lead sponsor
Indiana University
Collaborators
Agency for Healthcare Research and Quality (AHRQ)
Responsible party
Brownsyne Tucker Edmonds (Associate Professor of Obstetrics and Gynecology and Clinical Pediatrics, Indiana University) — Principal investigator
First posted
Mar 3, 2022
Start date
Jun 6, 2022
Primary completion
Nov 2027 (estimated)
Completion
Aug 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Shelley Hoffman, MPH
Contact
laymans@iu.edu
3172789636
Brownsyne Tucker Edmonds, MD, MPH, MS
principal investigator · Indiana University
Miriam Kuppermann, PhD, MPH
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion